ArticleNeuropsychopharmacology reports2022
Intracerebroventricular administration of oxytocin and intranasal administration of the oxytocin derivative improve β-amyloid peptide (25-35)-induced memory impairment in mice.
Article in Neuropsychopharmacology reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- Evaluating the Therapeutic Effects of Oxytocin on Animal Model of Alzheimer's Disease: A Systematic Review.Current Alzheimer research · 2025Pooled it
- Oxytocin Neuron-Specific CAPS2 Deficiency in Mice Impairs Hippocampal Plasticity and Long-Term Memory Through Reduced ERK Phosphorylation in the Ventral hippocampus.The European journal of neuroscience · 2026Article
- Sex differences in neuromodulatory subcortical systems and their implications for Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Review
- Current Perspectives on Oxytocin and Alzheimer's Disease-Related Symptoms.Current Alzheimer research · 2026Review
- Lower birth rate, greater female dementia risk: global and regional patterns and public health implications.Future science OA · 2025Article
- Association between oxytocin and S100B in community-dwelling older adults.PCN reports : psychiatry and clinical neurosciences · 2025Article
- Ex-vivo Imaging of Glial Energy Metabolism in the Neonatal Mouse Brain during Convulsive Seizures with Intranasal Radiotracer Administration.Molecular imaging and biology · 2025Article
- Intranasal Administration of Disulfiram in Rats Produces Rapid and Potent Anxiolytic-Like Effects Without Adverse Alcohol-Related Interactions.Advances in pharmacological and pharmaceutical sciences · 2025Article
- Targeting the hypothalamus for modeling age-related DNA methylation and developing OXT-GnRH combinational therapy against Alzheimer's disease-like pathologies in male mouse model.Nature communications · 2024Article
- Rosavin thwarts amyloid-β-induced macromolecular damages and neurotoxicity, exhibiting anti-Alzheimer's disease activity in Wister rat model.Inflammopharmacology · 2024Article
- The Role of Oxytocin in Alzheimer's Disease and Its Relationship with Social Interaction.Cells · 2023Review
- Association between serum oxytocin levels and depressive state in community-dwelling older adults: A cross-sectional study.PCN reports : psychiatry and clinical neurosciences · 2023Article
- Intranasal Polymeric and Lipid-Based Nanocarriers for CNS Drug Delivery.Pharmaceutics · 2023Review
- Linking Social Cognition, Parvalbumin Interneurons, and Oxytocin in Alzheimer's Disease: An Update.Journal of Alzheimer's disease : JAD · 2023Review
- Oxytocinergic projection from the hypothalamus to supramammillary nucleus drives recognition memory in mice.PloS one · 2023Article
- Intracerebroventricular administration of oxytocin and intranasal administration of the oxytocin derivative improve β-amyloid peptide (25-35)-induced memory impairment in mice.Neuropsychopharmacology reports · 2022Article
- Alternative Pharmacological Strategies for the Treatment of Alzheimer's Disease: Focus on Neuromodulator Function.Biomedicines · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimWe previously reported that oxytocin, a peptide hormone, can reverse the β-amyloid peptide (25-35) (Aβ
methodsThe Y-maze and Morris water maze (MWM) tests were performed. Since the intracerebroventricular (ICV) administration is both invasive and impractical, we further utilized intranasal (IN) delivery to the brain. For this purpose, we prepared an oxytocin derivative containing cell-penetrating peptides and a penetration accelerating sequence, which was subsequently used in our IN administration experiments.
resultsWe herein showed that the ICV administration of oxytocin in mice exerted memory-improving effects on the Aβ
conclusionOur results suggest that the oxytocin derivative is effective for its IN delivery to the brain and may be particularly useful in the clinical treatment of cognitive impairment, such as that characterizing AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.